原标题:中国生物制药子公司签订海外授权协议 合作开发纤维化创新药物 2月24日,中国生物发布公告称,子公司北京泰德制药与美国Graviton公司签订海外授权合作协议,在大中华区以外地区共同开发及商业化中国生物制药自主研发的治疗纤维化创新药TDI01。按开发和商业化进度,中国生物制药最高可获益5.175亿美元。 TDI01是国家十三五重大新药创制品种,可通过高选择性...
Source Link原标题:中国生物制药子公司签订海外授权协议 合作开发纤维化创新药物 2月24日,中国生物发布公告称,子公司北京泰德制药与美国Graviton公司签订海外授权合作协议,在大中华区以外地区共同开发及商业化中国生物制药自主研发的治疗纤维化创新药TDI01。按开发和商业化进度,中国生物制药最高可获益5.175亿美元。 TDI01是国家十三五重大新药创制品种,可通过高选择性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.